13F filer · CIK 1646343
NEXTHERA CAPITAL LP
NEW YORK, NY · filing since Q4 2015 · last filing Aug 14, 2019
Reported value
$120.1M
+$37.7M vs prior
Positions
23
New / sold out
11 / 12
Added / reduced
11 / 1
Turnover
35.9%
buys $76.3M · sells $36.3M
Top-10 weight
71.6%
Biggest buys vs Q1 2019
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Added | Intercept Pharmaceuticals Inc | +140,489 | +1175.4% | +$11.2M |
| New | Coherus Biosciences Inc | +316,316 | – | +$7.0M |
| New | Ascendis Pharma A/S | +60,266 | – | +$6.9M |
| New | Pacira BioSciences Inc | +149,086 | – | +$6.5M |
| Added | Neurocrine Biosciences Inc | +68,340 | +284.3% | +$5.8M |
| Added | Insmed Inc | +186,478 | +65.6% | +$4.8M |
| Added | Sarepta Therapeutics Inc | +29,047 | +136.6% | +$4.4M |
| New | AbbVie Inc | +52,681 | – | +$3.8M |
| New | Biohaven Pharmaceutical Holdin | +86,165 | – | +$3.8M |
| Added | Global Blood Therapeutics Inc | +55,206 | +63.4% | +$2.9M |
12 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Biggest sells vs Q1 2019
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Sold out | Heron Therapeutics Inc | -388,623 | -100.0% | $-9.5M |
| Sold out | Bausch Health Cos Inc | -205,660 | -100.0% | $-5.1M |
| Sold out | Stemline Therapeutics Inc | -325,526 | -100.0% | $-4.2M |
| Sold out | Novartis AG | -45,329 | -100.0% | $-3.8M |
| Sold out | Cymabay Therapeutics Inc | -210,257 | -100.0% | $-2.8M |
| Sold out | Exelixis Inc | -90,356 | -100.0% | $-2.1M |
| Sold out | Acorda Therapeutics Inc | -154,806 | -100.0% | $-2.1M |
| Reduced | Allergan PLC | -10,353 | -75.6% | $-1.7M |
| Sold out | Kiniksa Pharmaceuticals Ltd | -67,692 | -100.0% | $-1.2M |
| Sold out | Chiasma Inc | -203,948 | -100.0% | $-1.1M |
3 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2019
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | Intercept Pharmaceuticals IncCOM | 152,441 | $12.1M | 10.10% |
| 2 | Insmed IncCOM PAR $.01 | 470,741 | $12.1M | 10.04% |
| 3 | Audentes Therapeutics IncCOM | 294,013 | $11.1M | 9.27% |
| 4 | Neurocrine Biosciences IncCOM | 92,380 | $7.8M | 6.50% |
| 5 | Sarepta Therapeutics IncCOM | 50,317 | $7.6M | 6.37% |
| 6 | Global Blood Therapeutics IncCOM | 142,305 | $7.5M | 6.23% |
| 7 | Immunomedics IncCOM | 524,140 | $7.3M | 6.06% |
| 8 | Coherus Biosciences IncCOM | 316,316 | $7.0M | 5.82% |
| 9 | Ascendis Pharma A/SSPONSORED ADR | 60,266 | $6.9M | 5.78% |
| 10 | Pacira BioSciences IncCOM | 149,086 | $6.5M | 5.40% |
13 more rows. Subscribe for $29/month to see every row, download the data and use the API.